Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $11.80

Compass Therapeutics, Inc. (NASDAQ:CMPX) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $11.80.

Several analysts have recently commented on the stock. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $5.00 to $4.00 in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th.

Compass Therapeutics Price Performance

CMPX opened at $2.60 on Friday. The company’s 50 day simple moving average is $1.62 and its two-hundred day simple moving average is $1.50. Compass Therapeutics has a 1-year low of $0.76 and a 1-year high of $2.70. The firm has a market capitalization of $357.73 million, a price-to-earnings ratio of -7.03 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, equities analysts anticipate that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of Compass Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its holdings in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Compass Therapeutics by 12.4% in the second quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock worth $284,000 after acquiring an additional 31,433 shares in the last quarter. Barclays PLC grew its stake in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after acquiring an additional 112,614 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after acquiring an additional 70,200 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.